$33.0M
The Kent biotechnology spinout raised the capital from backers including XGEN Venture and the British Business Bank to push its lead treatment into clinical evaluation.
E
EpilepsyGTx
EpilepsyGTx develops targeted gene therapies for focal refractory epilepsy.
Kent, UK—Founded 2021
$33.0MTotal raised
A British biotechnology spinout developing targeted gene therapies for focal refractory epilepsy.
Categories
Founders
NK
Nicolas Koebel
Chief Executive Officer